Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.00%
)
US TECH 100
29,380.40
(
0.58%
)
Dow Jones
50,461.68
(
0.00%
)
Brent Oil
93.20
(
-3.90%
)
Bitcoin
75,233.34
(
-0.76%
)
News Focus
News Focus
Post# of 20689
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech2020 post# 15981

Thursday, 09/29/2016 9:08:48 AM

Thursday, September 29, 2016 9:08:48 AM

Post# of 20689
To re-iterate, the main issue in the 40mg-Copaxone patent case is obviousness. MNTA and its co-defendants will argue that giving twice as much Copaxone (approximately) half as often is not a bona fide innovation worthy of patent protection.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote